The deubiquitinating enzyme UCHL3 promotes anaplastic thyroid cancer progression and metastasis through Hippo signaling pathway
Related Experiment Video
Updated: Aug 9, 2025

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor
Published on: September 13, 2018
Jianing Tang1,2,3, Qian Yang3, Chao Mao4,5
1Department of Liver Surgery, Xiangya Hospital, Central South University, Changsha, 410078, Hunan, China.
Abstract:
Yes-associated protein (YAP) is one of major key effectors of the Hippo pathway and the mechanism supporting abnormal YAP expression in Anaplastic thyroid carcinoma (ATC) remains to be characterized. Here, we identified ubiquitin carboxyl terminal hydrolase L3 (UCHL3) as a bona fide deubiquitylase of YAP in ATC. UCHL3 stabilized YAP in a deubiquitylation activity-dependent manner. UCHL3 depletion significantly decreased ATC progression, stem-like and metastasis, and increased cell sensitivity to chemotherapy. Depletion of UCHL3 decreased the YAP protein level and the expression of YAP/TEAD target genes in ATC. UCHL3 promoter analysis revealed that TEAD4, through which YAP bind to DNA, activated UCHL3 transcription by binding to the promoter of UCHL3. In general, our results demonstrated that UCHL3 plays a pivotal role in stabilizing YAP, which in turn facilitates tumorigenesis in ATC, suggesting that UCHL3 may prove to be a potential target for the treatment of ATC.
Insights
Ubiquitin carboxyl terminal hydrolase L3 (UCHL3) stabilizes Yes-associated protein (YAP) in Anaplastic thyroid carcinoma (ATC). Inhibiting UCHL3 reduces ATC progression and increases chemotherapy sensitivity, suggesting UCHL3 as a potential therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The Hippo pathway effector Yes-associated protein (YAP) is crucial in cancer, but its regulation in Anaplastic thyroid carcinoma (ATC) is unclear.
- Understanding YAP regulation is vital for developing targeted therapies for aggressive thyroid cancers.
Purpose of the Study:
- To identify the deubiquitylase responsible for YAP stabilization in ATC.
- To investigate the role of this deubiquitylase in ATC progression and its potential as a therapeutic target.
Main Methods:
- Identified UCHL3 as a YAP deubiquitylase in ATC.
- Assessed the impact of UCHL3 depletion on ATC progression, stemness, metastasis, and chemotherapy sensitivity.
- Analyzed YAP protein levels and YAP/TEAD target gene expression following UCHL3 depletion.
- Investigated the transcriptional regulation of UCHL3 by TEAD4.
Main Results:
- UCHL3 deubiquitylates and stabilizes YAP in an activity-dependent manner.
- UCHL3 depletion significantly inhibited ATC progression, reduced stem-like properties and metastasis, and enhanced chemotherapy sensitivity.
- UCHL3 depletion decreased YAP protein levels and YAP/TEAD target gene expression.
- TEAD4 transcriptionally activated UCHL3 expression by binding to its promoter.
Conclusions:
- UCHL3 plays a critical role in stabilizing YAP, promoting tumorigenesis in ATC.
- UCHL3 represents a promising therapeutic target for Anaplastic thyroid carcinoma treatment.
More Related Videos
10:25Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology
Published on: November 22, 2024
11:32Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
Published on: March 27, 2020
Related Concept Videos
Hedgehog Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Anaphase Promoting Complex
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Abnormal Proliferation